ZenRx will provide an undisclosed up-front payment, milestones and royalties, and Zenith will commit resources to the Oraxol and Oratecan global development programs

Zealand Pharma A/S, of Copenhagen, Denmark, said licensing partner Sanofi SA, of Paris, provided an update in its first-quarter earnings on the status of the Lantus (insulin glargine)/Lyxumia (lixisenatide) single combination development program

The South Korean development program will run parallel with Almac's development program in Europe, where the cancer compound is entering Phase I/II trials in the UK

Selexis SA, of Geneva, closed an agreement with Ligand Pharmaceuticals Inc., of La Jolla, Calif., to sell potential milestone and royalty payments for more than 15 biologic development programs from Selexis...Selexis currently holds milestone and potential royalty interest payment rights to 14 more biologic development programs not included in the Ligand deal

The South Korean development program will run parallel with Almac's development program in Europe, where the cancer compound is entering Phase I/II trials in the UK

Biota Pharmaceuticals, Inc., of Rockville, Md., said its board of directors has adopted a revised corporate strategy that will shift their primary focus from early stage research to clinical-stage development programs that it could independently advance into late-stage development

Inc., of Whitehouse Station, N.J., and Luminex Corp., of Austin, Texas, signed a collaboration and license deal to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, an oral, beta amyloid precursor protein site cleaving enzyme inhibitor and Merck's lead candidate for Alzheimer's disease

Funds will be used to advance development programs across Bionomics' pipeline, including BNC375, Bionomics' drug candidate for the treatment of Alzheimer's disease and other conditions where memory is significantly compromised and Bionomics' cancer stem cell directed drug candidate BNC101...The volasertib clinical development program is the company's most advanced in cell cycle inhibition

The clinical development program was initiated in 2012, with the next steps including process development, GMP production, Phase Ia and Ib trials and preparations for Phase II studies

The funds will be used to pursue an advanced product development program for ladostigil, a molecule designed for the treatment of mild cognitive impairment (MCI) and early stages of Alzheimer's disease...PolyActiva said the funds will be used to further preclinical and clinical development programs, including intraocular implants to treat glaucoma and severe infections of the eye, along with an intraarticular product to treat osteoarthritis

KineMed Inc., of Emeryville, Calif., Isis Pharmaceuticals Inc., of Carlsbad, Calif., and CHDI Foundation Inc., of Los Angeles, will collaborate to apply KineMed's biomarker platform to Isis's antisense therapeutics development program for Huntington's disease, building on an earlier alliance between CHDI and KineMed

Domainex Ltd., of Cambridge, UK, is seeking to raise £1.5 million (US$2.32 million) to advance its kinase-based drug development programs for TBK1/KKe and epigenetics targets

Pursuant to the terms, each of the company's ordinary shares, including shares represented by American depositary shares (ADS), will be cancelled in exchange for the right to receive $2.20 in each per share, or $15.40 per ADS...Due to the oversubscription, the closing unit price was set at NIS3.544 per unit

Zealand Pharma A/S, of Copenhagen, Denmark, said it was notified that licensing partner Sanofi SA, of Paris, will delay development of a program combining recently approved Lyxumia (lixisenatide) with Sanofi's Lantus (insulin glargine), owing to a technical issue encountered during the development of the Fix-Flex combination device

Idenix Pharmaceuticals Inc., of Cambridge, Mass., said it has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in Phase IIb testing for hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the company had previously filed an investigational new drug application but had not initiated patient dosing

Soligenix Inc., of Princeton, N.J., said its OrbeShield (oral beclomethasone 17,21-dipropionate, or oral BDP) development program for the treatment of gastrointestinal acute radiation syndrome has received fast-track designation from the FDA

Velocity Pharmaceutical Development LLC, of South San Francisco, entered a licensing agreement with EuMederis Pharmaceuticals Inc., of San Diego, to pursue a drug development program using EuMederis' EuPort technology, which optimizes the pharmaceutical properties of peptide drugs

The grant is intended to support the company's research and development program for its stem cell therapy candidate NurOwn

The companies said the breakthrough is the culmination of a 12-month joint development program